Log in

NASDAQ:PULMPulmatrix Stock Price, Forecast & News

$1.68
-0.03 (-1.75 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.65
Now: $1.68
$1.74
50-Day Range
$1.25
MA: $1.53
$1.92
52-Week Range
$0.61
Now: $1.68
$2.06
Volume505,669 shs
Average Volume907,568 shs
Market Capitalization$42.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Read More
Pulmatrix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.91 million
Book Value$0.27 per share

Profitability

Net Income$-20,600,000.00
Net Margins-188.59%

Miscellaneous

Employees22
Market Cap$42.71 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

How has Pulmatrix's stock been impacted by COVID-19 (Coronavirus)?

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PULM shares have increased by 21.7% and is now trading at $1.68. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pulmatrix.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Pulmatrix.

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) released its quarterly earnings results on Thursday, May, 14th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. The biotechnology company had revenue of $2.76 million for the quarter. Pulmatrix had a negative return on equity of 107.55% and a negative net margin of 188.59%. View Pulmatrix's earnings history.

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Shares of Pulmatrix reverse split before market open on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PULM?

1 brokers have issued 1-year target prices for Pulmatrix's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Pulmatrix's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 495.2% from the stock's current price. View analysts' price targets for Pulmatrix.

Has Pulmatrix been receiving favorable news coverage?

Media stories about PULM stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pulmatrix earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutPulmatrix.

Are investors shorting Pulmatrix?

Pulmatrix saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,320,000 shares, a decline of 19.0% from the April 30th total of 1,630,000 shares. Based on an average trading volume of 992,500 shares, the short-interest ratio is currently 1.3 days. Currently, 7.1% of the company's shares are short sold. View Pulmatrix's Current Options Chain.

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Verastem (VSTM), Biocept (BIOC), Cronos Group (CRON), Evoke Pharma (EVOK), Ford Motor (F), Novavax (NVAX), Neovasc (NVCN) and AT&T (T).

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the following people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
  • Mr. William E. Duke Jr., CFO, Treasurer & Sec. (Age 47)
  • Dr. James M. Roach, Consultant (Age 59)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (2.31%) and Hussman Strategic Advisors Inc. (0.97%). View institutional ownership trends for Pulmatrix.

Which major investors are buying Pulmatrix stock?

PULM stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Hussman Strategic Advisors Inc.. View insider buying and selling activity for Pulmatrix.

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $1.68.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $42.71 million and generates $7.91 million in revenue each year. The biotechnology company earns $-20,600,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.

What is Pulmatrix's official website?

The official website for Pulmatrix is www.pulmatrix.com.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.